Needham raised the firm’s price target on ResMed to $236 from $224 and keeps a Buy rating on the shares. The company’s Q3 earnings and revenue topped estimates, but its organic revenue growth slowed to 7% from 9% in Q2 as ResMed faced a more difficult comp, the analyst tells investors in a research note. The firm believes however that the company can sustain mid- to high-single digit revenue growth, with much stronger EPS growth as its margins improve.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Australian Stocks: ResMed (RMD) Shares Surge on Robust Q3 Results
- Resmed Inc (RMD) Q3 Earnings Cheat Sheet
- RBC says small surprise in Lilly’s trial could be viewed as positive for ResMed
- Inspire rises, ResMed slips as Street digests data from Lilly sleep apnea trials
- KeyBanc views Lilly’s SURMOUNT-OSA results as ‘a bit of a relief’ for Inspire
